Bcli: initiation - potential 10x return on successful phase 3b. promising post hoc and biomarker analysis underpins our nurown® clinical effectiveness expectation

From acf equity research healthcare team nasdaq: bcli read acf equity research's initiation note here  read acf equity research's related thematic research note on regenerative medicine – neurodegenerative disease stem cells & als/mnd/lou gehrig's here london , june 14, 2024 /prnewswire/ --  initiation note: brainstorm cell therapeutics inc. (nasdaq: bcli) is focused on developing autologous mesenchymal stem cell (msc) therapies for the treatment of neurodegenerative diseases (ndds) – bcli's primary target is the fatal amyotrophic lateral sclerosis (als/mnd/lou gehrig's). post hoc analysis of bcli's piii trial data shows bcli's nurown® (debamestrocel, msc-ntf), has statistically significant clinical effects on early-stage als sufferers and that placebo trialists deteriorate faster.
BCLI Ratings Summary
BCLI Quant Ranking